TW221378B - - Google Patents
Info
- Publication number
- TW221378B TW221378B TW081108170A TW81108170A TW221378B TW 221378 B TW221378 B TW 221378B TW 081108170 A TW081108170 A TW 081108170A TW 81108170 A TW81108170 A TW 81108170A TW 221378 B TW221378 B TW 221378B
- Authority
- TW
- Taiwan
- Prior art keywords
- matter
- compositions
- preventing
- amount
- antibiotic
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77786491A | 1991-10-16 | 1991-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW221378B true TW221378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1994-03-01 |
Family
ID=25111545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW081108170A TW221378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-10-16 | 1992-10-14 |
Country Status (27)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948688A (en) * | 1991-10-16 | 1999-09-07 | Schering Corporation | Method of determining monomeric drug content |
| US6380172B1 (en) | 1991-10-16 | 2002-04-30 | Schering Corporation | Monomeric lipophilic oligosaccharide antibiotic compositions |
| US5652226A (en) * | 1995-12-22 | 1997-07-29 | Schering Corporation | Water soluble antibiotics |
| US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
| US5763600A (en) * | 1997-04-18 | 1998-06-09 | Schering Corporation | Oligosaccharide antibiotics and process for preparation thereof |
| KR100680014B1 (ko) * | 1997-10-03 | 2007-02-09 | 갈레니카 파마슈티칼스 인크. | 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도 |
| US6162910A (en) * | 1998-11-30 | 2000-12-19 | Schering Corporation | Process for preparing lipophilic oligosaccharide antibiotics |
| US6320044B1 (en) | 1998-12-18 | 2001-11-20 | Schering Corporation | Process for recovering lipophilic oligosaccharide antibiotics |
| WO2000037670A1 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Process for recovering lipophilic oligosaccharide antibiotics |
| WO2001039573A2 (de) * | 1999-12-01 | 2001-06-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Verwendung von lungensurfactant zur behandlung von legionärskrankheit |
| US6861513B2 (en) | 2000-01-12 | 2005-03-01 | Schering Corporation | Everninomicin biosynthetic genes |
| US6858584B2 (en) * | 2000-05-02 | 2005-02-22 | Theravance, Inc. | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
| US6699505B2 (en) * | 2000-10-17 | 2004-03-02 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by compexing with cyclodextrins |
| DE10109166A1 (de) * | 2001-02-25 | 2002-09-12 | Combinature Biopharm Ag | Avilamycin-Derivate |
| EP1730163A4 (en) * | 2004-03-17 | 2009-12-30 | Panacos Pharmaceuticals Inc | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid |
| EP1987935A3 (en) * | 2004-12-01 | 2008-11-19 | Nitto Denko Corporation | Foam Filling Member |
| CN101160132A (zh) * | 2005-04-12 | 2008-04-09 | 帕纳克斯医药公司 | 3-o-(3′,3′-二甲基琥珀酰基)桦木酸二-n-甲基-d-葡萄糖胺的多晶形物 |
| CN101855336B (zh) | 2007-09-14 | 2019-07-30 | 赛诺菲巴斯德生物制剂有限责任公司 | 含艰难梭菌类毒素a和b的药物组合物 |
| JP2010095454A (ja) * | 2008-10-14 | 2010-04-30 | Cyclochem:Kk | 抗菌組成物 |
| EP4324483A3 (en) * | 2011-01-14 | 2024-05-01 | Emory University | Oligosaccharide conjugates for targeting bacteria and uses related thereto |
| CN107847517A (zh) | 2015-06-10 | 2018-03-27 | 维瑟公司 | 羟丙基β‑环糊精组合物及方法 |
| CN106317143B (zh) * | 2016-08-23 | 2020-10-30 | 河北圣雪大成制药有限责任公司 | 一种提取阿维拉霉素的方法 |
| WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
| CN117024611B (zh) * | 2023-03-01 | 2024-05-17 | 中国科学院南海海洋研究所 | 寡糖类抗生素everninomicin高产菌株的构建及活性的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR128F (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1962-04-02 | |||
| US3915956A (en) * | 1973-07-09 | 1975-10-28 | Schering Corp | Reduction products of everninomicins and methods for their manufacture |
| US3920629A (en) * | 1973-09-19 | 1975-11-18 | Schering Corp | Desevernitrose everninomicins and method for their manufacture |
| US4006225A (en) * | 1973-10-31 | 1977-02-01 | Schering Corporation | Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor |
| US3998708A (en) * | 1976-01-19 | 1976-12-21 | Schering Corporation | Electrochemical process for preparing hydroxylaminoeverninomicins |
| US4027016A (en) * | 1976-01-19 | 1977-05-31 | Schering Corporation | Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor |
| US4129720A (en) * | 1977-02-14 | 1978-12-12 | Schering Corporation | Aminoeverninomicin and derivatives thereof |
| US4597968A (en) * | 1982-08-06 | 1986-07-01 | Schering Corporation | Antibiotic 13-384 complex from Micromonospora carbonacea var africana |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4735903A (en) * | 1984-06-21 | 1988-04-05 | Schering Corporation | Micromonospora carbonacea var africana |
| US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US4622314A (en) * | 1985-10-15 | 1986-11-11 | Schering Corporation | Substituted oligosaccharide antibiotics |
| US4767748A (en) * | 1985-10-15 | 1988-07-30 | Schering Corporation | Substituted oligosaccharide antibodies |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
-
1992
- 1992-10-14 DE DE69221252T patent/DE69221252T2/de not_active Expired - Fee Related
- 1992-10-14 JP JP5507719A patent/JP2614407B2/ja not_active Expired - Lifetime
- 1992-10-14 US US08/211,700 patent/US5624914A/en not_active Expired - Lifetime
- 1992-10-14 AT AT92309368T patent/ATE156019T1/de not_active IP Right Cessation
- 1992-10-14 WO PCT/US1992/008565 patent/WO1993007904A1/en not_active Application Discontinuation
- 1992-10-14 PL PL92303189A patent/PL170591B1/pl unknown
- 1992-10-14 EP EP92309368A patent/EP0538011B1/en not_active Expired - Lifetime
- 1992-10-14 ES ES92309368T patent/ES2104845T3/es not_active Expired - Lifetime
- 1992-10-14 YU YU92192A patent/YU48722B/sh unknown
- 1992-10-14 CA CA002121345A patent/CA2121345C/en not_active Expired - Fee Related
- 1992-10-14 PH PH45109A patent/PH31675A/en unknown
- 1992-10-14 TW TW081108170A patent/TW221378B/zh active
- 1992-10-14 EP EP92921991A patent/EP0610295A1/en active Pending
- 1992-10-14 AU AU27806/92A patent/AU678344B2/en not_active Ceased
- 1992-10-14 NZ NZ244735A patent/NZ244735A/en unknown
- 1992-10-14 ZA ZA927923A patent/ZA927923B/xx unknown
- 1992-10-14 DK DK92309368.6T patent/DK0538011T3/da active
- 1992-10-14 KR KR1019940701247A patent/KR100249584B1/ko not_active Expired - Fee Related
- 1992-10-14 HU HU9401104A patent/HUT75157A/hu unknown
- 1992-10-15 MX MX9205922A patent/MX9205922A/es not_active IP Right Cessation
- 1992-10-15 CN CN92112388A patent/CN1035923C/zh not_active Expired - Fee Related
- 1992-10-15 IL IL10344692A patent/IL103446A/xx not_active IP Right Cessation
- 1992-10-16 SI SI19929200260A patent/SI9200260A/sl unknown
- 1992-10-16 HR HR07/777,864A patent/HRP921069B1/xx not_active IP Right Cessation
-
1994
- 1994-04-08 NO NO941276A patent/NO307326B1/no not_active IP Right Cessation
- 1994-04-14 FI FI941723A patent/FI941723A0/fi unknown
-
1997
- 1997-09-19 GR GR970402434T patent/GR3024800T3/el unknown
-
1998
- 1998-01-09 HK HK98100167A patent/HK1001085A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW221378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| GB9104890D0 (en) | Compositions | |
| NZ244021A (en) | Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof | |
| HUT61989A (en) | Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient | |
| TW355683B (en) | Composition containing micronized nebivolol | |
| AU2724292A (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| HUT64013A (en) | Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
| HUT61004A (en) | Process for producing quinoxaline derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| IL94819A0 (en) | 11beta-aryl-4-estrene derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| BG104436A (en) | The administration of macrolides for the treatment of cancer and macular degeneration | |
| IL101358A0 (en) | Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it | |
| EP0620004A4 (en) | MEDICAL COMPOSITION. | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| GEP20032970B (en) | Pharmaceutical Compositions of Tizoxanide and Nitazoxanide | |
| PL308580A1 (en) | Solid pharmaceutical composition for oral administration and method of preparing same | |
| DK0524696T3 (da) | Orale præparater indeholdende dapiprazol | |
| AP9801235A0 (en) | Erythromycin derivatives. | |
| IL97648A0 (en) | Stabilized 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof | |
| IE43125L (en) | Aminoglycoside derivative | |
| IL57513A0 (en) | 1,3-diaminopropan-2-ol derivatives,their preparation and pharmaceutical compositions containing them | |
| MXPA99003849A (es) | Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina. | |
| BG103985A (en) | Multicyclic derivatives of erythromycin |